Florida, USA-based Axogen (Nasdaq: AXGN), which is developing and marketing innovative solutions for peripheral nerve injuries, has announced the appointment of Jens Schroeder Kemp to the newly created role of chief marketing officer.
Mr Kemp brings more than 20 years of strategic marketing, sales, and business development experience in high-growing medical technology.
As a member of the Axogen executive leadership team, Mr Kemp will report directly to Karen Zaderej, chairman, chief executive and president, and will oversee the development and execution of the company’s marketing strategies.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze